SCHEMBL6822984

SCHEMBL6822984

CCOC(=O)c1cccc2cccnc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
HSD17B10 Q99714 3/20 0.57
HTT P42858 2/20 0.57
HPGD P15428 2/20 0.57
KDM4E B2RXH2 1/20 0.57
TP53 P04637 1/20 0.57
PARP1 P09874 1/20 0.57
TSHR P16473 1/20 0.56
POLB P06746 1/20 0.54
CDC25B P30305 2/20 0.52
NPC1 O15118 1/20 0.52
CASP3 P42574 1/20 0.52
RAB9A P51151 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.51
KDR P35968 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11846633 0.88 ALDH1A1 (0.58) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL4832881 0.85 ALDH1A1 (0.54) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL11855800 0.84 ALDH1A1 (0.59) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL344528 0.82 ALDH1A1 (0.65) ALDH1A1HTTKDM4EPARP1POLB
SCHEMBL15465667 0.81 TSHR (0.56) ALDH1A1HSD17B10HTTKDM4ETSHR
SCHEMBL14040562 0.81 ALDH1A1 (0.63) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL22918322 0.81 EGLN1 (0.74) ALDH1A1PARP1TSHRPOLBCASP3
SCHEMBL11860480 0.81 CYP3A4 (0.59) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL9652662 0.81 PARP1 (0.56) ALDH1A1HSD17B10HTTHPGDKDM4E
SCHEMBL4832487 0.80 ALDH1A1 (0.50) ALDH1A1HSD17B10HTTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO claimed
US-3959473-A DIURETIC U.S. PHILIPS CORPORATION (US) 1976-05-25 US claimed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
EP-3183757-B1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM CLAP CO LTD (KR) 2022-05-04 EP disclosed
CN-107004768-B Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2020-08-21 CN disclosed
US-10454037-B2 Organic semiconductor composition comprising a liquid medium BASF SE (DE) 2019-10-22 US disclosed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US disclosed
US-10043978-B2 Organic semiconductor formulations FLEXTERRA, INC. (US) 2018-08-07 US disclosed
US-20170250347-A1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING A LIQUID MEDIUM BASF SE (DE) 2017-08-31 US disclosed
CN-107074857-A Method for preparing crystallization organic semiconducting materials 巴斯夫欧洲公司 2017-08-18 CN disclosed
WO-2016027217-A1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM BASF SE (DE) 2016-02-25 WO disclosed
WO-2016027218-A1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL BASF SE (DE) 2016-02-25 WO disclosed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 US disclosed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO disclosed
US-20030212100-A1 Quinoline derivatives and medicinal use thereof MITSUI CHEMICALS, INC. (JP) 2003-11-13 US disclosed
EP-1266888-A1 QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF Mitsui Chemicals, Inc. (JP) 2002-12-18 EP disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed
US-3959473-A DIURETIC U.S. PHILIPS CORPORATION (US) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212100-A1 Quinoline derivatives and medicinal use thereof PPARG, PPARD, PPARA ALDH1A1 822/4885HSD17B10 984/4885HTT 1453/4885
US-20170250347-A1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING A LIQUID MEDIUM CRY1, NEFM, OR10J3 ALDH1A1 4298/4885HSD17B10 4629/4885HTT 3830/4885
US-10454037-B2 Organic semiconductor composition comprising a liquid medium CRY1, NEFM, OR10J3 ALDH1A1 4298/4885HSD17B10 4629/4885HTT 3830/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885HSD17B10 4363/4885HTT 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.